Understanding Mechanisms of Whole Brain and Regional Grey Matter Atrophy in Children With MOGAD
ABSTRACT Objective To investigate the mechanisms driving whole brain and regional grey matter (GM) volume changes along with their clinical correlates in paediatric myelin oligodendrocyte glycoprotein antibody (MOG‐Ab)–associated disease (MOGAD). Methods One‐hundred‐nine paediatric MOGAD patients from two UK centres underwent MRI at attack nadir and ...
Ermelinda De Meo+14 more
wiley +1 more source
Isabelle Devos, Julie de Groot and Ariadne Schmidt (eds.), Single Life and the City, 1200-1900.
Sara M. Butler
doaj
Social Participation and Depressive Symptoms Among Older Adults.
Takemura Y+5 more
europepmc +1 more source
Association of social isolation, loneliness and risk of cardiovascular diseases: Meta-analysis of cohort studies. [PDF]
Wang L, Pan H, Cai Z, Li X, Luo L.
europepmc +1 more source
In Vitro Modeling of Natural Killer Cell Cytotoxicity to Inform Personalized ALS Therapeutics
ABSTRACT Objective Natural killer (NK) cells might contribute to motor neuron death in amyotrophic lateral sclerosis (ALS) through direct cytotoxicity, a process that could be inhibited with the FDA‐approved JAK/STAT pathway inhibitor, tofacitinib. This study aimed to verify that tofacitinib can suppress NK cell cytotoxicity, investigate if immune cell
Benjamin J. Murdock+8 more
wiley +1 more source
Ad Knotter (ed.), Limburg kolenland. Studies over de geschiedenis van de Limburgse kolenmijnbouw.
Loek Kreukels
doaj
Machine learning-based risk factor analysis and prediction model construction for mortality in chronic heart failure. [PDF]
Xu Q+6 more
europepmc +1 more source
Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji+9 more
wiley +1 more source